Marinus Pharmaceuticals, Inc.
GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX

Last updated:

Abstract:

The disclosure to methods for treating tuberous sclerosis complex or tuberous sclerosis complex-related epilepsy, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutically acceptable pregnenolone neurosteroid, such as ganaxolone, to reduce one or more symptoms of tuberous sclerosis complex or tuberous sclerosis complex-related epilepsy.

Status:
Application
Type:

Utility

Filling date:

1 Mar 2022

Issue date:

7 Jul 2022